A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmett

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    High Risk, Non-muscle Invasive Bladder Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1. Patients must have been diagnosed with high risk non-muscle-invasive (T1, high grade Ta and / or carcinoma in situ) transitional cell carcinoma of the bladder

    2. Absence of resectable disease after at least 2 cystoscopy /transurethral

You may not be eligible for this study if the following are true:

  • 1.  Patients with muscle invasive (T2, T3, or T4) locally advanced non-resectable or metastatic urothelial carcinoma


    2.  Patient has concurrent extra-vesical non-muscle invasive transitional cell carcinoma of the urothelium

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.